Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function.
A low molecular weight peptide of about 800-1000 having a negative inotropic effect. It is released into the circulation during experimental hemorrhagic pancreatitis, severe ischemia, and postoligemic shock.
The combination of hemodialysis and hemofiltration either simultaneously or sequentially. Convective transport (hemofiltration) may be better for removal of larger molecular weight substances and diffusive transport (hemodialysis) for smaller molecular weight solutes.
Decreased URINE output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1 ml/kg/hr depending on the age.
The quality of not being miscible with another given substance without a chemical change. One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction. (Dorland, 27th ed; Stedman, 25th ed)
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
Devices which can substitute for normally functioning KIDNEYS in removing components from the blood by DIALYSIS that are normally eliminated in the URINE.
Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the kidneys.
Surgery of the upper jaw bone usually performed to correct upper and lower jaw misalignment.
Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present.
Health care provided to a critically ill patient during a medical emergency or crisis.
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
Myoglobinuria is the presence of myoglobin, a protein found in muscle fibers, in the urine, which can occur due to muscle injury or disease, and may lead to acute kidney injury if excessive.
A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include, but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
Polymers where the main polymer chain comprises recurring amide groups. These compounds are generally formed from combinations of diamines, diacids, and amino acids and yield fibers, sheeting, or extruded forms used in textiles, gels, filters, sutures, contact lenses, and other biomaterials.
Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as DIABETES MELLITUS; LEUKEMIA; or LIVER FAILURE.
Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, they do not fall into another group of products.
Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.
Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION.
The adhesion of gases, liquids, or dissolved solids onto a surface. It includes adsorptive phenomena of bacteria and viruses onto surfaces as well. ABSORPTION into the substance may follow but not necessarily.
A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.
A disease or state in which death is possible or imminent.
Acrylic resins, also known as polymethyl methacrylate (PMMA), are a type of synthetic resin formed from polymerized methyl methacrylate monomers, used in various medical applications such as dental restorations, orthopedic implants, and ophthalmic lenses due to their biocompatibility, durability, and transparency.
Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs.

Bioavailability and metabolism of hydroquinone after intratracheal instillation in male rats. (1/340)

The purpose of this study was to investigate the rate and extent of hydroquinone (HQ) absorption and first pass metabolism in the lungs of male rats in vivo. [14C]HQ in physiological saline was administered intratracheally via an indwelling endotracheal tube to simulate inhalation exposure to HQ dust. The bioavailability of HQ was determined by blood sampling simultaneously at arterial and venous sites beginning immediately after administration to conscious rats. Pulmonary absorption and metabolism, and systemic metabolism and elimination were determined by chromatographic analysis of parent compound and metabolites in blood samples after intratracheal administration of [14C]HQ at 0.1, 1.0, and 10 mg/kg. Pulmonary absorption of HQ was found to be very rapid with [14C]HQ detectable in arterial blood, and to a lesser extent in venous blood, within 5 to 10 s after dose administration. Only [14C]HQ was detected in the initial (5-10 s) arterial blood samples at all dose levels, indicating that pulmonary metabolism of HQ was not extensive. However, later blood samples (45-720 s) indicated rapid metabolism and elimination of the parent compound and metabolites after intratracheal absorption. The elimination half-life from the 0.1 mg/kg dose was allometrically scaled to human proportions and used to estimate the steady-state (maximum) human blood concentrations of HQ resulting from presupposed workplace exposures. The estimates indicated minimal levels of HQ in human blood after respiratory exposures of greater than 1 h at 0.1 or 2.0 mg/m3; these levels were less than background concentrations of HQ detected in human blood in previous studies.  (+info)

Extracorporeal rheopheresis in the treatment of acute ischemic stroke: A randomized pilot study. (2/340)

BACKGROUND AND PURPOSE: Extracorporeal rheopheresis is a safe method to optimize hemorheology. Our aim was to determine whether treatment with extracorporeal rheopheresis in patients with acute ischemic hemispheric stroke improves cerebral perfusion as assessed with serial 99mTc-ethyl-cysteinate-dimer single-photon emission CT (99mTc-ECD SPECT). We also investigated how clinical outcome is associated with treatment and imaging results. METHODS: Thirty-three patients (mean age, 64+/-10 years) with acute ischemic hemispheric stroke were included in a prospective, randomized, parallel group pilot study. First treatment with or without extracorporeal rheopheresis took place within 12 hours after the onset of symptoms and was repeated 3 times at intervals of 24 hours. Hemorheological parameters were measured before and after each session. Each patient underwent 99mTc-ECD SPECT immediately before treatment, 6 to 8 hours after treatment, and after 5 days. A semiquantitative SPECT graded scale was used to measure depth and extent of activity deficits and thus to quantify the perfusion deficit. RESULTS: Seventeen patients were actively treated with extracorporeal rheopheresis, and 16 patients did not receive extracorporeal rheopheresis. After 3 months, no differences were found in the functional or neurological outcome. Despite a rapid, sustained decrease of plasma viscosity and erythrocyte aggregation in the rheopheresis group, there was no significant difference in the SPECT graded scale after therapy between the 2 groups. Patients with early reperfusion (decrease in the SPECT graded scale >25% 6 to 8 hours after therapy compared with the baseline examination) experienced a better functional outcome (Modified Rankin Scale) after 3 months compared with patients without reperfusion (P=0.04). CONCLUSIONS: Since quantitative flow mapping and clinical follow-up did not reveal any differences between patients who were treated with extracorporeal rheopheresis and controls, it appears very unlikely that extracorporeal rheopheresis enhances reperfusion after acute cerebral ischemia.  (+info)

Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. (3/340)

BACKGROUND: Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration (CVVH). Despite adequate exogenous anticoagulation, the occlusion of CVVH circuits can occur within minutes to a few hours of use and is associated with evidence of thrombin generation. Having found no evidence of activation of the contact factor (intrinsic coagulation) pathway during CVVH, we sought to examine the effect of the first episode of CVVH on the tissue factor (extrinsic) pathway of coagulation and thrombin generation. METHODS: Twelve critically ill patients were studied prior to the commencement of hemofiltration and at regular intervals thereafter until the filter clotted. RESULTS: Prior to hemofiltration, most patients had increased levels of plasma tissue factor, thrombin-antithrombin (TAT) complexes, and tissue factor pathway inhibitor (TFPI); during hemofiltration, further generation of TAT complexes occurred. Initially, levels of activated factor VII (FVIIa) fell and TFPI increased, but during the course of hemofiltration, the levels of TFPI fell and FVIIa increased. Levels of tissue factor increased during CVVH in some patients, but this was not related to the generation of FVIIa. CONCLUSIONS: These data indicate that activation of FVII occurred during CVVH, which was related to levels of TFPI, but not tissue factor, and was coincidental to thrombin generation.  (+info)

Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs. (4/340)

OBJECTIVE: To examine the impact of continuous venovenous hemofiltration (CVVH) on the course of experimental pancreatitis in pigs. SUMMARY BACKGROUND DATA: The activation of different mediator cascades is assumed to trigger multiple organ dysfunction or failure during necrotizing pancreatitis. CVVH has been suggested to be beneficial in those instances by eliminating several inflammatory mediators released in the circulation. METHODS: Pancreatitis was induced by a combined intraductal injection of sodium taurocholate and enterokinase. Control group animals received no treatment after induction. A second group underwent "therapeutic" CVVH after a 20% decline of mean arterial pressure. In the third group, "prophylactic" CVVH was started simultaneously with the induction of pancreatitis. The concentrations of tumor necrosis factor-alpha, transforming growth factor-beta1, kinin, and phospholipase A2 were measured at different time points in blood (pre- and postfilter) and in the hemofiltrate to calculate the respective sieving coefficients that reflect most accurately the plasma clearance of mediators by CVVH. RESULTS: Survival time was significantly prolonged both by therapeutic and prophylactic CVVH; it was more pronounced in the latter. CVVH did not influence the increase in transforming growth factor concentrations. However, 6 hours after induction, the increases of plasma concentrations of tumor necrosis factor, phospholipase, and kinin were significantly weakened by CVVH compared with controls. In the treatment groups, the plasma concentrations of tumor necrosis factor and phospholipase showed a significant negative correlation with the respective sieving coefficients, which decreased in the later course of the experiments. CONCLUSIONS: Experimental necrotizing pancreatitis was associated with a tremendous increase of plasma concentrations of tumor necrosis factor, phospholipase, and kinin. The effective removal of these mediators by CVVH resulted in significantly improved survival time. Animals that received prophylactic CVVH had a longer survival period than those in which CVVH was started after clinical impairment. The decreasing efficiency of CVVH in eliminating inflammatory mediators in the later course of the experiments suggested that the filter membranes were compromised by long-term application. These findings provide further evidence that CVVH offers therapeutic options even in the absence of conventional indications for blood-purifying treatments.  (+info)

Cytokine removal during continuous hemofiltration in septic patients. (5/340)

A potential application of the continuous renal replacement therapies is the extracorporeal removal of inflammatory mediators in septic patients. Cytokine elimination with continuous renal replacement therapies has been demonstrated in several clinical studies, but so far without important effects on their serum concentrations. Improved knowledge of the cytokine removal mechanisms could lead to the development of more efficient treatment strategies. In the present study, 15 patients with septic shock and acute renal failure were observed during the first 24 h of treatment with continuous venovenous hemofiltration (CVVH) with an AN69 membrane. After 12 h, the hemofilter was replaced and the blood flow rate (QB) was switched from 100 ml/min to 200 ml/min or vice versa. Pre- and postfilter plasma and ultrafiltrate concentrations of selected inflammatory and anti-inflammatory cytokines were measured at several time points allowing the calculation of a mass balance. Cytokine removal was highest 1 h after the start of CVVH and after the change of the membrane (ranging from 25 to 43% of the prefilter amount), corresponding with a significant fall in the serum concentration of all cytokines. The inhibitors of inflammation were removed to the same extent as the inflammatory cytokines. Adsorption to the AN69 membrane appeared to be the main clearance mechanism, being most pronounced immediately after installation of a new membrane and decreasing steadily thereafter, indicating rapid saturation of the membrane. A QB of 200 ml/min was associated with a 75% increase of the ultrafiltration rate and a significantly higher convective elimination and membrane adsorption than at a QB of 100 ml/min. The results indicate that optimal cytokine removal with CVVH with an AN69 membrane could be achieved with a combination of a high QB/ultrafiltration rate and frequent membrane changes.  (+info)

Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. (6/340)

BACKGROUND: Systemic heparinization is associated with a high rate of bleeding when used to maintain patency of the extracorporeal circuit during continuous renal replacement therapy (CRRT) in critically ill patients. Regional anticoagulation can be achieved with citrate, but previously described techniques are cumbersome and associated with metabolic complications. METHODS: We designed a simplified system for delivering regional citrate anticoagulation during continuous venovenous hemofiltration (CVVH). We evaluated filter life and hemorrhagic complications in the first 17 consecutive patients who received this therapy at our institution. Blood flow rate was set at 180 ml/min. Ultrafiltration rate was maintained at 2.0 liters/hr and citrate-based replacement fluid (trisodium citrate 13.3 mM, sodium chloride 100 mM, magnesium chloride 0.75 mM, dextrose 0.2%) was infused proximal to the filter to maintain the desired fluid balance. Calcium gluconate was infused through a separate line to maintain a serum-ionized calcium level of 1.0 to 1.1 mM. RESULTS: All patients were critically ill and required mechanical ventilation and vasopressor therapy. Systemic heparin anticoagulation was judged to be contraindicated in all of the patients. A total of 85 filters were used, of which 64 were lost because of clotting, with a mean life span of 29.5 +/- 17.9 hours. The remaining 21 filters were discontinued for other reasons. Control of fluid and electrolyte balance and azotemia was excellent (mean serum creatinine after 48 to 72 hr of treatment was 2.4 +/- 1.2 mg/dl). No bleeding episodes occurred. Two patients, one with septic shock and the other with fulminant hepatic failure, developed evidence for citrate toxicity without a significant alteration in clinical status. Nine patients survived (52.9%). CONCLUSION: Our simplified technique of regional anticoagulation with citrate is an effective and safe form of anticoagulation for CVVH in critically ill patients with a high risk of bleeding.  (+info)

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. (7/340)

BACKGROUND: Patients with acute renal failure (ARF) have high morbidity and mortality rates, particularly if they have serious comorbid conditions. Several studies indicate that in rats with ARF caused by ischemia or certain nephrotoxins, insulin-like growth factor-I (IGF-I) enhances the recovery of renal function and suppresses protein catabolism. METHODS: Our objective was to determine whether injections of recombinant human IGF-I (rhIGF-I) would enhance the recovery of renal function and is safe in patients with ARF. The study was designed as a randomized, double-blind, placebo-controlled trial in intensive care units in 20 teaching hospitals. Seventy-two patients with ARF were randomized to receive rhIGF-I (35 patients) or placebo (37 patients). The most common causes of ARF in the rhIGF-I and placebo groups were, respectively, sepsis (37 and 35% of patients) and hypotension or hemodynamic shock (42 and 27% of patients). At baseline, the mean (+/- SD) APACHE II scores in the rhIGF-I and placebo-treated groups were 24 +/- 5 and 25 +/- 8, respectively. In the rhIGF-I and placebo groups, the mean (median) urine volume and urinary iothalamate clearances (glomerular filtration rate) were 1116 +/- 1037 (887) and 1402 +/- 1183 (1430) ml/24 hr and 6.4 +/- 5.9 (4.3) and 8.7 +/- 7.2 (4.4) ml/min and did not differ between the two groups. Patients were injected subcutaneously every 12 hours with rhIGF-I, 100 microgram/kg desirable body weight, or placebo for up to 14 days. Injections were started within six days of the onset of ARF. The primary end-point was a change in glomerular filtration rate from baseline. Other end points included changes from baseline in urine volume, creatinine clearance and serum urea, creatinine, albumin and transferrin, frequency of hemodialysis or ultrafiltration, and mortality rate. RESULTS: During the treatment period, which averaged 10.7 +/- 4.1 and 10.6 +/- 4.5 days in the rhIGF-I and placebo groups, there were no differences in the changes from baseline values of the glomerular filtration rate, creatinine clearance, daily urine volume, or serum urea nitrogen, creatinine, albumin or transferrin. In patients who did not receive renal replacement therapy, there was also no significant difference in serum creatinine and urea between the two groups. Twenty patients in the rhIGF-I group and 17 placebo-treated patients underwent dialysis or ultrafiltration. Twelve rhIGF-I-treated patients and 12 placebo-treated patients died during the 28 days after the onset of treatment. CONCLUSIONS: rhIGF-I does not accelerate the recovery of renal function in ARF patients with substantial comorbidity.  (+info)

Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. (8/340)

BACKGROUND: There has been much recent interest in accumulation of advanced glycation end-products (AGE) in uraemic patients. Analysis of AGE has been difficult, because commonly used methodologies, i.e. immunodetection assays or fluorescence measurements, reflect group reactivity and are not specific for chemically defined substances. Some investigators measured individual AGE compounds, e.g. pentosidine, carboxymethyllysine, pyrraline or imidazolone, but a systematic assessment of known compounds using specific HPLC methods in diabetic and non-diabetic end-stage renal disease (ESRD) patients during treatment has not been performed. METHODS: For the present study, the concentrations of early and late products of the Maillard reaction in plasma and ultrafiltrate were monitored during high-flux dialysis sessions in diabetic and non-diabetic patients. AGE were analysed by fluorescence spectroscopy and size exclusion chromatography with fluorescence detection. Specific HPLC methods were used to quantify the Amadori product fructoselysine and the AGE compounds pentosidine and pyrraline in acid or enzymatic hydrolysates. RESULTS: Using size exclusion chromatography, we confirmed a similar fluorescent peak distribution for diabetic and non-diabetic ESRD patients. Main fractions were found at approximately 70, approximately 14 and <2 kDa, confirming results obtained by other authors. In diabetic patients, the fluorescence intensity of the low molecular weight fraction was higher. Uraemic patients differed from controls mainly by the fluorescence of the low molecular weight fraction. The peak spectrum in ultrafiltrates was similar to that in plasma regarding low molecular weight fractions and the 14 kDa peak, but no protein-bound fluorescence was found at 70 kDa. HPLC analysis revealed a significant reduction of plasma pentosidine during high-flux dialysis in non-diabetic (from 9.1+/-5.1 to 8.5+/-4.7 pmol/mg protein; P<0.05) and diabetic patients (from 10.0+/-9.1 to 6.8+/-4.0 pmol/mg protein; P<0.05). In contrast, plasma fructoselysine showed only a non-significant trend to decrease in diabetic (from 3.24+/-0.88 to 3.05+/-0.77 nmol/mg protein) and non-diabetic patients (from 2.69+/-0.52 to 2.56+/-0.50 nmol/mg protein). Pyrraline, a nonfluorescent late AGE product derived from reaction of 3-deoxyglucosone with lysine, could not be detected (detection limit approximately 40 pmol/mg protein). Comparing HPLC and size exclusion analysis, it was found that pentosidine accumulated in the range of low molecular weight substances and was removed by high-flux dialysis. CONCLUSIONS: High-flux dialysis reduces the plasma concentration of fluorescent AGE compounds, i.e. pentosidine, but the Amadori product fructoselysine is not removed, indicating that this compound is protein associated.  (+info)

Hemofiltration is a type of renal replacement therapy used for treating acute or chronic renal failure. It is a convective process that utilizes a semipermeable membrane to remove waste solutes and water from the blood. In this process, blood is passed through a filter, called a hemofilter, which contains hollow fibers with tiny pores. The pressure gradient across the membrane causes fluid and solutes to move from the blood into the filtrate compartment, based on their size and charge.

The filtrate, which contains waste products and water, is then discarded, while a replacement solution is infused back into the patient's bloodstream to maintain adequate fluid volume and electrolyte balance. Hemofiltration can be performed continuously (continuous hemofiltration) or intermittently (intermittent hemofiltration), depending on the clinical situation and the patient's needs.

Hemofiltration is particularly useful in critically ill patients with fluid overload, electrolyte imbalances, or acute kidney injury, as it can effectively remove large volumes of water and solutes, including inflammatory mediators and toxins, from the blood. It is also used in the management of drug overdoses and poisonings, where rapid removal of toxic substances is required.

I'm sorry for any confusion, but "Myocardial Depressant Factor" is not a widely recognized or accepted medical term in the context of a defined disease entity or specific pathological process. It appears to be a historical term that was used in some research studies related to sepsis and septic shock during the 1970s and 1980s.

During those times, researchers proposed the existence of a "Myocardial Depressant Factor" (MDF) as a possible explanation for the reversible myocardial dysfunction observed in sepsis. However, the exact identity and nature of this MDF remained elusive and unproven, with various substances such as cytokines, prostaglandins, and free radicals being suggested as potential candidates.

Over time, the concept of a specific "Myocardial Depressant Factor" has largely fallen out of favor in the medical community. Instead, the current understanding of sepsis-induced myocardial dysfunction is that it is likely to be multifactorial, involving various inflammatory mediators, microvascular dysfunction, and direct cellular injury.

Hemodiafiltration (HDF) is a type of renal replacement therapy used for patients with severe kidney failure. It combines elements of hemodialysis and hemofiltration to provide more efficient removal of waste products, toxins, and excess fluid from the blood.

During HDF, the patient's blood is passed through a semi-permeable membrane in a dialyzer or artificial kidney. The membrane allows for the passage of smaller molecules such as urea, creatinine, and electrolytes, while retaining larger molecules like proteins. A combination of diffusion (due to the concentration gradient) and convection (due to the application of a transmembrane pressure) leads to the removal of waste products and toxins from the blood.

In addition to this, a substitution fluid is infused into the extracorporeal circuit to replace the volume of fluid removed during convection. This substitution fluid can be tailored to match the patient's electrolyte and acid-base status, allowing for better control over their biochemical parameters.

HDF has been shown to provide better clearance of middle and large molecular weight uremic toxins compared to conventional hemodialysis, potentially leading to improved clinical outcomes such as reduced inflammation, oxidative stress, and cardiovascular risk. However, more research is needed to confirm these benefits and establish the optimal dosing and prescription for HDF.

Oliguria is a medical term that refers to a condition where the urine output is significantly reduced, typically defined as less than 400 milliliters (or about 13 ounces) in 24 hours for an adult. This condition can be a sign of underlying kidney dysfunction or other medical conditions that affect urine production, such as dehydration, shock, or obstruction of the urinary tract. It is important to note that oliguria can be a serious symptom and requires prompt medical attention to determine the cause and initiate appropriate treatment.

Drug incompatibility refers to a situation where two or more drugs cannot be mixed, combined, or administered together because they will interact in a way that reduces their effectiveness, causes unintended side effects, or even results in harm to the patient. This can occur due to chemical reactions between the drugs, physical interactions (such as precipitation), or pharmacological interactions (such as one drug inhibiting the metabolism of another).

Drug incompatibilities can be identified through various methods, including laboratory testing, literature review, and clinical experience. Healthcare professionals must be aware of potential drug incompatibilities and take steps to avoid them when prescribing or administering medications to patients. This may involve using different administration routes, changing the timing of medication administration, or selecting alternative drugs that are compatible with each other.

Acute kidney injury (AKI), also known as acute renal failure, is a rapid loss of kidney function that occurs over a few hours or days. It is defined as an increase in the serum creatinine level by 0.3 mg/dL within 48 hours or an increase in the creatinine level to more than 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days, or a urine volume of less than 0.5 mL/kg per hour for six hours.

AKI can be caused by a variety of conditions, including decreased blood flow to the kidneys, obstruction of the urinary tract, exposure to toxic substances, and certain medications. Symptoms of AKI may include decreased urine output, fluid retention, electrolyte imbalances, and metabolic acidosis. Treatment typically involves addressing the underlying cause of the injury and providing supportive care, such as dialysis, to help maintain kidney function until the injury resolves.

Artificial kidney, also known as a renal replacement therapy or dialysis, is a device that performs the essential functions of the human kidney when the natural kidneys are unable to do so. The main function of an artificial kidney is to filter and remove waste, excess water, and toxic substances from the blood, helping to maintain the body's chemical balance and regulate blood pressure.

There are two primary types of artificial kidney treatments: hemodialysis and peritoneal dialysis. Hemodialysis involves circulating the patient's blood through an external filter (dialyzer) that contains a semi-permeable membrane, which separates waste products and excess fluids from the blood. The cleaned blood is then returned to the body. This process typically takes place in a clinical setting, such as a hospital or dialysis center, for about 3-5 hours, several times a week.

Peritoneal dialysis, on the other hand, uses the patient's own peritoneum (a membrane lining the abdominal cavity) as a natural filter. A special solution called dialysate is introduced into the peritoneal cavity via a catheter, and waste products and excess fluids pass from the blood vessels in the peritoneum into the dialysate. After a dwell time of several hours, the used dialysate is drained out and replaced with fresh solution. This process can be performed manually (continuous ambulatory peritoneal dialysis) or using a machine (automated peritoneal dialysis), typically at home and during sleep.

Artificial kidneys are life-saving treatments for patients with end-stage renal disease, helping them maintain their quality of life and extend their lifespan until a kidney transplant becomes available.

Renal replacement therapy (RRT) is a medical treatment that takes over the normal function of the kidneys when they fail. The main objectives of RRT are to remove waste products and excess fluid, correct electrolyte imbalances, and maintain acid-base balance in the body. There are several types of RRT, including hemodialysis, peritoneal dialysis, and kidney transplantation.

Hemodialysis involves circulating the patient's blood through an external filter called a dialyzer, which removes waste products and excess fluid. The cleaned blood is then returned to the patient's body. Hemodialysis can be performed in a hospital or dialysis center, or at home with appropriate training.

Peritoneal dialysis involves instilling a special solution called dialysate into the patient's abdominal cavity, where it remains for a period of time to allow waste products and excess fluid to move from the bloodstream into the dialysate through a membrane in the peritoneum. The used dialysate is then drained out of the body and replaced with fresh dialysate. Peritoneal dialysis can be performed continuously or intermittently, and it can also be done at home.

Kidney transplantation involves surgically implanting a healthy kidney from a donor into the patient's body to replace the failed kidneys. This is usually the most effective form of RRT, but it requires major surgery and long-term immunosuppressive therapy to prevent rejection of the transplanted organ.

Overall, RRT is a life-sustaining treatment for patients with end-stage kidney disease, and it can significantly improve their quality of life and longevity.

A maxillary osteotomy is a surgical procedure that involves making cuts in the bone of the upper jaw (maxilla). This type of surgery may be performed for various reasons, such as to correct jaw deformities, realign the jaws, or treat sleep apnea. In some cases, it may also be done in conjunction with other procedures, such as a genioplasty (chin surgery) or rhinoplasty (nose surgery).

During a maxillary osteotomy, an incision is made inside the mouth, and the surgeon carefully cuts through the bone of the upper jaw. The maxilla is then repositioned as needed and held in place with small plates and screws. In some cases, bone grafts may also be used to help support the new position of the jaw. After the surgery, the incision is closed with stitches.

It's important to note that a maxillary osteotomy is a complex surgical procedure that requires careful planning and execution. It should only be performed by an experienced oral and maxillofacial surgeon or craniofacial surgeon. As with any surgery, there are risks involved, including infection, bleeding, and reactions to anesthesia. It's important to discuss these risks with your surgeon and to follow all post-operative instructions carefully to help ensure a successful recovery.

Anuria is a medical condition characterized by the absence or near-absence of urine output, typically defined as less than 100 milliliters in 24 hours. This occurs when the kidneys are unable to produce urine due to a complete or nearly complete failure of both kidneys' function. Anuria can be caused by various underlying medical conditions such as severe dehydration, kidney damage, obstruction in the urinary tract, or certain medications that affect kidney function. It is considered a serious medical emergency and requires immediate evaluation and treatment to prevent further complications, including potential permanent kidney damage or even death.

Critical care, also known as intensive care, is a medical specialty that deals with the diagnosis and management of life-threatening conditions that require close monitoring and organ support. Critical care medicine is practiced in critical care units (ICUs) or intensive care units of hospitals. The goal of critical care is to prevent further deterioration of the patient's condition, to support failing organs, and to treat any underlying conditions that may have caused the patient to become critically ill.

Critical care involves a multidisciplinary team approach, including intensivists (specialist doctors trained in critical care), nurses, respiratory therapists, pharmacists, and other healthcare professionals. The care provided in the ICU is highly specialized and often involves advanced medical technology such as mechanical ventilation, dialysis, and continuous renal replacement therapy.

Patients who require critical care may have a wide range of conditions, including severe infections, respiratory failure, cardiovascular instability, neurological emergencies, and multi-organ dysfunction syndrome (MODS). Critical care is an essential component of modern healthcare and has significantly improved the outcomes of critically ill patients.

Sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs. It is characterized by a whole-body inflammatory state (systemic inflammation) that can lead to blood clotting issues, tissue damage, and multiple organ failure.

Sepsis happens when an infection you already have triggers a chain reaction throughout your body. Infections that lead to sepsis most often start in the lungs, urinary tract, skin, or gastrointestinal tract.

Sepsis is a medical emergency. If you suspect sepsis, seek immediate medical attention. Early recognition and treatment of sepsis are crucial to improve outcomes. Treatment usually involves antibiotics, intravenous fluids, and may require oxygen, medication to raise blood pressure, and corticosteroids. In severe cases, surgery may be required to clear the infection.

Myoglobinuria is a medical condition characterized by the presence of myoglobin in the urine. Myoglobin is a protein found in muscle cells that is released into the bloodstream when muscle tissue is damaged or broken down, such as during intense exercise, trauma, or muscle diseases like muscular dystrophy and rhabdomyolysis.

When myoglobin is present in high concentrations in the blood, it can damage the kidneys by causing direct tubular injury, cast formation, and obstruction, which can lead to acute kidney injury (AKI) or even renal failure if left untreated. Symptoms of myoglobinuria may include dark-colored urine, muscle pain, weakness, and swelling, as well as symptoms related to AKI such as nausea, vomiting, and decreased urine output.

Diagnosis of myoglobinuria is typically made by detecting myoglobin in the urine using a dipstick test or more specific tests like immunoassays or mass spectrometry. Treatment may involve aggressive fluid resuscitation, alkalization of the urine to prevent myoglobin precipitation, and management of any underlying conditions causing muscle damage.

Multiple Organ Failure (MOF) is a severe condition characterized by the dysfunction or failure of more than one organ system in the body. It often occurs as a result of serious illness, trauma, or infection, such as sepsis. The organs that commonly fail include the lungs, kidneys, liver, and heart. This condition can lead to significant morbidity and mortality if not promptly diagnosed and treated.

The definition of MOF has evolved over time, but a widely accepted one is the "Sequential Organ Failure Assessment" (SOFA) score, which evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, renal, and neurologic. A SOFA score of 10 or more indicates MOF, and a higher score is associated with worse outcomes.

MOF can be classified as primary or secondary. Primary MOF occurs when the initial insult directly causes organ dysfunction, such as in severe trauma or septic shock. Secondary MOF occurs when the initial injury or illness has been controlled, but organ dysfunction develops later due to ongoing inflammation and other factors.

Early recognition and aggressive management of MOF are crucial for improving outcomes. Treatment typically involves supportive care, such as mechanical ventilation, dialysis, and medication to support cardiovascular function. In some cases, surgery or other interventions may be necessary to address the underlying cause of organ dysfunction.

Septic shock is a serious condition that occurs as a complication of an infection that has spread throughout the body. It's characterized by a severe drop in blood pressure and abnormalities in cellular metabolism, which can lead to organ failure and death if not promptly treated.

In septic shock, the immune system overreacts to an infection, releasing an overwhelming amount of inflammatory chemicals into the bloodstream. This leads to widespread inflammation, blood vessel dilation, and leaky blood vessels, which can cause fluid to leak out of the blood vessels and into surrounding tissues. As a result, the heart may not be able to pump enough blood to vital organs, leading to organ failure.

Septic shock is often caused by bacterial infections, but it can also be caused by fungal or viral infections. It's most commonly seen in people with weakened immune systems, such as those who have recently undergone surgery, have chronic medical conditions, or are taking medications that suppress the immune system.

Prompt diagnosis and treatment of septic shock is critical to prevent long-term complications and improve outcomes. Treatment typically involves aggressive antibiotic therapy, intravenous fluids, vasopressors to maintain blood pressure, and supportive care in an intensive care unit (ICU).

I believe there may be some confusion in your question. "Nylons" is a common term for a type of synthetic fiber often used in clothing, hosiery, and other textile applications. It is not a medical term or concept. If you have any questions related to medical terminology or concepts, I would be happy to try and help clarify!

Lactic acidosis is a medical condition characterized by an excess accumulation of lactic acid in the body. Lactic acid is a byproduct produced in the muscles and other tissues during periods of low oxygen supply or increased energy demand. Under normal circumstances, lactic acid is quickly metabolized and cleared from the body. However, when the production of lactic acid exceeds its clearance, it can lead to a state of acidosis, where the pH of the blood becomes too acidic.

Lactic acidosis can be caused by several factors, including:

* Prolonged exercise or strenuous physical activity
* Severe illness or infection
* Certain medications, such as metformin and isoniazid
* Alcoholism
* Hypoxia (low oxygen levels) due to lung disease, heart failure, or anemia
* Inherited metabolic disorders that affect the body's ability to metabolize lactic acid

Symptoms of lactic acidosis may include rapid breathing, fatigue, muscle weakness, nausea, vomiting, and abdominal pain. Severe cases can lead to coma, organ failure, and even death. Treatment typically involves addressing the underlying cause of the condition and providing supportive care, such as administering intravenous fluids and bicarbonate to help restore normal pH levels.

"Pharmaceutical solutions" is a term that refers to medications or drugs that are formulated in a liquid state, as opposed to solid forms like tablets or capsules. These solutions are typically created by dissolving the active pharmaceutical ingredient (API) in a solvent, such as water or ethanol, along with other excipients that help stabilize and preserve the solution.

Pharmaceutical solutions can be administered to patients through various routes, including oral, intravenous, subcutaneous, or intramuscular injection, depending on the desired site of action and the specific properties of the drug. Some examples of pharmaceutical solutions include antibiotic infusions, pain medications, and electrolyte replacement drinks.

It's important to note that the term "pharmaceutical solutions" can also refer more broadly to the process of developing and manufacturing drugs, as well as to the industry as a whole. However, in a medical context, it most commonly refers to liquid medications.

Rhabdomyolysis is a medical condition characterized by the breakdown and degeneration of skeletal muscle fibers, leading to the release of their intracellular contents into the bloodstream. This can result in various complications, including electrolyte imbalances, kidney injury or failure, and potentially life-threatening conditions if not promptly diagnosed and treated.

The process of rhabdomyolysis typically involves three key components:

1. Muscle injury: Direct trauma, excessive exertion, prolonged immobilization, infections, metabolic disorders, toxins, or medications can cause muscle damage, leading to the release of intracellular components into the bloodstream.
2. Release of muscle contents: When muscle fibers break down, they release various substances, such as myoglobin, creatine kinase (CK), lactate dehydrogenase (LDH), aldolase, and potassium ions. Myoglobin is a protein that can cause kidney damage when present in high concentrations in the bloodstream, particularly when it is filtered through the kidneys and deposits in the renal tubules.
3. Systemic effects: The release of muscle contents into the bloodstream can lead to various systemic complications, such as electrolyte imbalances (particularly hyperkalemia), acidosis, hypocalcemia, and kidney injury or failure due to myoglobin-induced tubular damage.

Symptoms of rhabdomyolysis can vary widely depending on the severity and extent of muscle damage but may include muscle pain, weakness, swelling, stiffness, dark urine, and tea-colored or cola-colored urine due to myoglobinuria. In severe cases, patients may experience symptoms related to kidney failure, such as nausea, vomiting, fatigue, and decreased urine output.

Diagnosis of rhabdomyolysis typically involves measuring blood levels of muscle enzymes (such as CK and LDH) and evaluating renal function through blood tests and urinalysis. Treatment generally focuses on addressing the underlying cause of muscle damage, maintaining fluid balance, correcting electrolyte imbalances, and preventing or managing kidney injury.

Artificial membranes are synthetic or man-made materials that possess properties similar to natural biological membranes, such as selective permeability and barrier functions. These membranes can be designed to control the movement of molecules, ions, or cells across them, making them useful in various medical and biotechnological applications.

Examples of artificial membranes include:

1. Dialysis membranes: Used in hemodialysis for patients with renal failure, these semi-permeable membranes filter waste products and excess fluids from the blood while retaining essential proteins and cells.
2. Hemofiltration membranes: Utilized in extracorporeal circuits to remove larger molecules, such as cytokines or inflammatory mediators, from the blood during critical illnesses or sepsis.
3. Drug delivery systems: Artificial membranes can be used to encapsulate drugs, allowing for controlled release and targeted drug delivery in specific tissues or cells.
4. Tissue engineering: Synthetic membranes serve as scaffolds for cell growth and tissue regeneration, guiding the formation of new functional tissues.
5. Biosensors: Artificial membranes can be integrated into biosensing devices to selectively detect and quantify biomolecules, such as proteins or nucleic acids, in diagnostic applications.
6. Microfluidics: Artificial membranes are used in microfluidic systems for lab-on-a-chip applications, enabling the manipulation and analysis of small volumes of fluids for various medical and biological purposes.

Adsorption is a process in which atoms, ions, or molecules from a gas, liquid, or dissolved solid accumulate on the surface of a material. This occurs because the particles in the adsorbate (the substance being adsorbed) have forces that attract them to the surface of the adsorbent (the material that the adsorbate is adhering to).

In medical terms, adsorption can refer to the use of materials with adsorptive properties to remove harmful substances from the body. For example, activated charcoal is sometimes used in the treatment of poisoning because it can adsorb a variety of toxic substances and prevent them from being absorbed into the bloodstream.

It's important to note that adsorption is different from absorption, which refers to the process by which a substance is taken up and distributed throughout a material or tissue.

Amikacin is a type of antibiotic known as an aminoglycoside, which is used to treat various bacterial infections. It works by binding to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death. Amikacin is often used to treat serious infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. It may be given intravenously or intramuscularly, depending on the severity and location of the infection. As with all antibiotics, amikacin should be used judiciously to prevent the development of antibiotic resistance.

A critical illness is a serious condition that has the potential to cause long-term or permanent disability, or even death. It often requires intensive care and life support from medical professionals. Critical illnesses can include conditions such as:

1. Heart attack
2. Stroke
3. Organ failure (such as kidney, liver, or lung)
4. Severe infections (such as sepsis)
5. Coma or brain injury
6. Major trauma
7. Cancer that has spread to other parts of the body

These conditions can cause significant physical and emotional stress on patients and their families, and often require extensive medical treatment, rehabilitation, and long-term care. Critical illness insurance is a type of insurance policy that provides financial benefits to help cover the costs associated with treating these serious medical conditions.

Acrylic resins are a type of synthetic polymer made from methacrylate monomers. They are widely used in various industrial, commercial, and medical applications due to their unique properties such as transparency, durability, resistance to breakage, and ease of coloring or molding. In the medical field, acrylic resins are often used to make dental restorations like false teeth and fillings, medical devices like intraocular lenses, and surgical instruments. They can also be found in orthopedic implants, bone cement, and other medical-grade plastics. Acrylic resins are biocompatible, meaning they do not typically cause adverse reactions when in contact with living tissue. However, they may release small amounts of potentially toxic chemicals over time, so their long-term safety in certain applications is still a subject of ongoing research.

Cardiopulmonary bypass (CPB) is a medical procedure that temporarily takes over the functions of the heart and lungs during major heart surgery. It allows the surgeon to operate on a still, bloodless heart.

During CPB, the patient's blood is circulated outside the body with the help of a heart-lung machine. The machine pumps the blood through a oxygenator, where it is oxygenated and then returned to the body. This bypasses the heart and lungs, hence the name "cardiopulmonary bypass."

CPB involves several components, including a pump, oxygenator, heat exchanger, and tubing. The patient's blood is drained from the heart through cannulas (tubes) and passed through the oxygenator, where it is oxygenated and carbon dioxide is removed. The oxygenated blood is then warmed to body temperature in a heat exchanger before being pumped back into the body.

While on CPB, the patient's heart is stopped with the help of cardioplegia solution, which is infused directly into the coronary arteries. This helps to protect the heart muscle during surgery. The surgeon can then operate on a still and bloodless heart, allowing for more precise surgical repair.

After the surgery is complete, the patient is gradually weaned off CPB, and the heart is restarted with the help of electrical stimulation or medication. The patient's condition is closely monitored during this time to ensure that their heart and lungs are functioning properly.

While CPB has revolutionized heart surgery and allowed for more complex procedures to be performed, it is not without risks. These include bleeding, infection, stroke, kidney damage, and inflammation. However, with advances in technology and technique, the risks associated with CPB have been significantly reduced over time.

However, solute movement with hemofiltration is governed by convection rather than by diffusion. With hemofiltration, dialysate ... slow extended hemofiltration), or as CHF (continuous hemofiltration), also sometimes called continuous veno-venous ... Hemofiltration is most commonly used in an intensive care unit setting, where it is either given as 8- to 12-hour treatments, ... During hemofiltration, a patient's blood is passed through a set of tubing (a filtration circuit) via a machine to a ...
"Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double ... "Citrate anticoagulation for continuous venovenous hemofiltration". Critical Care Medicine. 37 (2): 545-552. doi:10.1097/CCM. ...
"Outcome in children receiving continuous venovenous hemofiltration". Pediatrics. 107 (6): 1309-12. doi:10.1542/peds.107.6.1309 ...
Exchange transfusion, hemodialysis, or hemofiltration may be used. A diet with carefully controlled levels of the amino acids ...
... or hemofiltration. Intralipid infusion therapy is indicated in cases of imminent risk of cardiac arrest in order to scavenge ...
... or hemofiltration. Control of caffeine intake requires awareness of the caffeine content of caffeinated beverages, over-the- ...
Scheler invented the term of hemofiltration, and was co-inventor and pioneer in the development of hemofiltration, a process ... Later the different techniques of hemofiltration (CAVH, CVVH etc.) were further developed. Hemofiltration was regarded by ... He was a pioneer in the field of hemofiltration treatment and helped found an institute for drug law at the University of ... After the invention of hemofiltration, and the early, tragic death of Peter Kramer, he increasingly focussed on his work at the ...
Hemofiltration or ultrafiltration devices constitute the third major type of blood salvage in operating rooms. In general, ... "Six different hemofiltration devices for blood conservation in cardiac surgery". Ann Thorac Surg. 51 (5): 747-53. doi:10.1016/ ...
Note that this is a different process to the related technique of hemofiltration. Three primary methods are used to gain access ... versus lactate-buffered solutions for acute continuous hemodiafiltration or hemofiltration". Cochrane Database of Systematic ...
In some situations, hemofiltration (purification of the blood) is temporarily required. In rare chronic forms of lactic ... Direct removal of lactate from the body (e.g. with hemofiltration or dialysis) is difficult, with limited evidence for benefit ...
Hemofiltration is more effective at removing large molecules from the bloodstream, such as myoglobin, but this does not seem to ... Its advantage over continuous hemofiltration is that one machine can be used multiple times a day, and that continuous ... Other treatments may include dialysis or hemofiltration in more severe cases. Once urine output is established, sodium ... Three main modalities of RRT are available: hemodialysis, continuous hemofiltration and peritoneal dialysis. The former two ...
Continuous dialysis or hemofiltration have proven to be the most effective treatment. Nutritional support and sodium benzoate ...
"Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study". Crit Care. 11 ...
Alwall pioneered the technique of ultrafiltration and introduced the principle of hemofiltration. Alwall is referred to as the ...
Alwall pioneered the technique of ultrafiltration and introduced the principle of hemofiltration. Alwall is referred to as the ...
"Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration". ...
Treatment options for protein toxicity can include renal replacement therapies like hemodialysis and hemofiltration. Lifestyle ...
Unlike hemodialysis, hemofiltration and hemodiafiltration, no dialysate or replacement fluids are used in SCUF. Ultrafiltration ...
The decision to initiate dialysis or hemofiltration in patients with kidney failure depends on several factors. These can be ... Hemodiafiltration is a combination between hemodialysis and hemofiltration, thus used to purify the blood from toxins when the ... Hemofiltration is a similar treatment to hemodialysis, but it makes use of a different principle. The blood is pumped through a ... hemofiltration (primary), hemodiafiltration (secondary) and intestinal dialysis (secondary). In hemodialysis, the patient's ...
"Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report". Critical Care. 9 (2 ...
Artificial organ Kidney Dialysis Tissue engineering Microelectromechanical systems Nanotechnology Hemodialysis Hemofiltration " ...
... hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. Supportive ...
... continuous hemofiltration (CHF) continuous arteriovenous hemofiltration (CAVH or CAVHF) continuous venovenous hemofiltration ( ... intermittent hemofiltration (IHF) intermittent venovenous hemofiltration (IVVH or IVVHF) intermittent hemodiafiltration (IHDF) ... "Anticoagulation in Continuous Arteriovenous Hemofiltration", Arteriovenous Hemofiltration, Berlin, Heidelberg: Springer Berlin ... Hemodialysis, hemofiltration, and hemodiafiltration can be continuous or intermittent and can use an arteriovenous route (in ...
... no dosage adjustments are needed in people undergoing continuous hemofiltration, although more frequent administration may be ...
Hemodialysis and hemofiltration can also be used as options to remove potassium from the bloodstream when hyperkalemia is ...
Apheresis Autotransfusion Hemodialysis Hemofiltration Plasmapheresis Extracorporeal carbon dioxide removal Extracorporeal ...
May 2005). "Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed ...
... acute kidney injury and continuous hemofiltration, and nutrition in critical illness. He has been president of the American ...
Most cited papers: Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D (1995): Hemofiltration in human sepsis: ... Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances.Kidney Int. 1995 Nov;48(5):1563-70. ... Hoffmann started his scientific work with a publication about the elimination of inflammatory mediators via hemofiltration in ...
... hemofiltration MeSH H01.181.529.365.807.300.300 - hemodiafiltration MeSH H01.181.529.400 - hydrogen bonding MeSH H01.181. ... hemofiltration MeSH H01.671.100.534.807.300.300 - hemodiafiltration MeSH H01.671.100.552 - hemorheology MeSH H01.671.100.708 - ...
  • Hemofiltration is sometimes used in combination with hemodialysis, when it is termed hemodiafiltration. (wikipedia.org)
  • Here, the scalable bottom-up fabrication of wafer-scale carbon nanotube (CNT) membranes with highly aligned, low-friction, straight-channels/capillaries and narrow pore-diameter distributions (≈0.5-4.5 nm) is demonstrated, to overcome persistent challenges in hemofiltration/hemodialysis. (lu.se)
  • Using fluorescein isothiocyanate (FITC)-Ficoll 70 and albumin in phosphate buffered saline (PBS) as well as in bovine blood plasma, it is shown that CNT membranes can allow for significantly higher hydraulic permeability (more than an order of magnitude when normalized to pore area) than commercial high-flux hemofiltration/hemodialysis membranes (HF 400), as well as greatly enhance removal of middle molecules while maintaining comparable albumin retention. (lu.se)
  • The unique transport characteristics of CNTs coupled with size-exclusion and wafer-scale fabrication offer transformative advances for hemofiltration, and the obtained insight into molecular transport can aid advancements in several other bio-systems/applications beyond hemofiltration/hemodialysis. (lu.se)
  • Continuous veno-venous hemofiltration is only used until your child is stable enough to receive hemodialysis treatment or experiences the recovery of his or her kidney function. (rileychildrens.org)
  • Continuous veno-venous hemofiltration (CVVH) is a temporary treatment for patients who are critically ill, have acute kidney injury and are not stable enough to receive hemodialysis. (rileychildrens.org)
  • Continuous hemofiltration and hemodialysis procedures filter and dialyze blood without interruption. (msdmanuals.com)
  • Joe Basha, CCP and Minh Tran, CCP review what Continuous Veno-Venous Hemofiltration (CVVH) is and the differences between CVVH and Intermittent Hemodialysis (IHD). (perfusioneducation.com)
  • Misra M. Hemodialysis and hemofiltration. (medlineplus.gov)
  • Treatment includes hemofiltration, hemodialysis or kidney transplantation. (vanderbilt.edu)
  • Hemofiltration and hemodialysis support the kidneys by filtering toxins and waste products from blood. (vanderbilt.edu)
  • Removal of lithium should be achieved by discontinuation of the drug as well as extracorporeal removal by means of hemodialysis or continuous veno-venous hemofiltration (CVVH). (neurology.org)
  • Hemofiltration is most commonly used in an intensive care unit setting, where it is either given as 8- to 12-hour treatments, so called SLEF (slow extended hemofiltration), or as CHF (continuous hemofiltration), also sometimes called continuous veno-venous hemofiltration (CVVH) or continuous renal replacement therapy (CRRT). (wikipedia.org)
  • Continuous veno-venous hemofiltration (CVVH) is a type of dialysis used to care for critically ill children with acute kidney injury (a condition in which the kidneys suddenly stop performing their normal functions). (rileychildrens.org)
  • Objective: To report a sieving coefficient for peramivir in a patient receiving continuous venovenous hemofiltration (CVVH). (northwestern.edu)
  • The aim of the study was to investigate whether hemofilter passage of blood in continuous veno-venous hemofiltration (CVVH) alters MV composition and levels in critically ill patients with sepsis. (springeropen.com)
  • Continuous veno-venous hemofiltration (CVVH) is a frequently used renal replacement therapy (RRT) modality in critically ill patients [ 1 ]. (springeropen.com)
  • After observing two cases of repeated hemofiltration-filter clotting associated with high anti-PF4/heparin antibody concentrations, we systematically measured the anti-PF4/heparin antibody concentration in all cases of unexpected and repeated hemofiltration-filter clotting during continuous veno-venous hemofiltration (CVVH). (wustl.edu)
  • With extracorporeal membrane oxygenation and in-line hemofiltration, he recovered from repeated cardiac arrest and hyperkalemia. (ekja.org)
  • Furthermore, various technological advancement which mainly comprises high permeability hemofiltration and high volume permeability since the advent of continuous renal replacement therapy is also expected to boost the global CRRT market. (delveinsight.com)
  • Continuous Hemofiltration and Platelet Function in Critically Ill Patients: Retraction. (medscape.com)
  • Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. (medscape.com)
  • Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. (medscape.com)
  • As in dialysis, in hemofiltration one achieves movement of solutes across a semi-permeable membrane. (wikipedia.org)
  • Our results indicate that continuous arteriovenous hemofiltration, when vascular access consists of a Quinton-Scribner shunt, is a simple and effective method for the treatment of fluid overload resistant to pharmacologic therapy and to treat uremia in patients for whom the traditional methods of extracorporeal depuration are contraindicated. (karger.com)
  • Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. (medscape.com)
  • Management of subsequent fluid overload necessitated a brief period of hemofiltration. (endocrine-abstracts.org)
  • Combining ECMO and in-line hemofiltration might be a safe and effective technique for refractory hyperkalemic cardiac arrest and rhabdomyolysis in patients with DMD. (ekja.org)
  • We here report a case of a successful application of a combination of ECMO and in-line hemofiltration for a patient who suffered acute hyperkalemic cardiac arrest after orthopedic surgery. (ekja.org)
  • After the use of ECMO and in-line hemofiltration, he recovered from the repeated cardiac arrest and hyperkalemia. (ekja.org)
  • Patients requiring ECMO at the time of hemofiltration were excluded. (hindawi.com)
  • Hemofiltration is an effective blood purification technique for patients with renal failure and possibly also eliminates inflammatory mediators in the setting of sepsis. (springeropen.com)
  • During continuous veno-venous hemofiltration, a machine does the usual work of the kidneys. (rileychildrens.org)
  • Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study. (wustl.edu)
  • citation needed] Continuous hemofiltration (CHF) was first described in a 1977 paper by Kramer et al. (wikipedia.org)
  • METHODS: We reviewed the charts of all patients who had an anti-PF4/heparin antibody assay performed for repeated hemofiltration-filter clotting between November 2004 and May 2006 in our surgical intensive care unit. (wustl.edu)
  • Over the past 60 years, due to the advancement of hemo- the Work Group and tasked it with planning, developing, dialysis (HD) technology and the introduction of medical reviewing, and disseminating appropriate HD treatment insurance, dialysis treatment has become widespread, en- guidelines in accordance with international standards. (bvsalud.org)
  • In the article " High-Performance Hemofiltration via Molecular Sieving and Ultra-Low Friction in Carbon Nanotube Capillary Membranes ," published in the journal Advanced Functional Materials on Aug. 27, Kidambi and his co-authors demonstrate that their dialysis membranes made up of carbon nanotubes and polymers create a new paradigm for dialysis. (vanderbilt.edu)
  • During hemofiltration, a patient's blood is passed through a set of tubing (a filtration circuit) via a machine to a semipermeable membrane (the filter) where waste products and water (collectively called ultrafiltrate) are removed by convection. (wikipedia.org)
  • CONCLUSION: Repeated hemofiltration-filter clotting in less than 6 hours was often associated with the presence of anti-PF4/heparin antibodies, regardless of the platelet count. (wustl.edu)
  • Hemofiltration, also haemofiltration, is a renal replacement therapy which is used in the intensive care setting. (wikipedia.org)
  • The woman was connected to high-flow oxygen and hemofiltration was performed with sorption of cytokines. (pravmir.com)
  • The aim of this study was to identify factors associated with positive anti-PF4/heparin antibody in the case of repeated hemofiltration-filter clotting. (wustl.edu)